HIV-2 Integrase Variation in Senegal
Author Information
Author(s): Gottlieb Geoffrey S., Smith Robert A., Dia Badiane Ndeye Mery, Ba Selly, Hawes Stephen E., Toure Macoumba, Starling Alison K., Traore Fatou, Sall Fatima, Cherne Stephen L., Stern Joshua, Wong Kim G., Lu Paul, Kim Moon, Raugi Dana N., Lam Airin, Mullins James I., Kiviat Nancy B., Papa Salif Sow
Primary Institution: University of Washington
Hypothesis
Intrinsic HIV-2 integrase variation at 'secondary' HIV-1 INI-resistance sites may affect the genetic barrier to HIV-2 INI resistance.
Conclusion
HIV-2 is susceptible to integrase inhibitors, with no primary mutations for resistance found in the studied cohort.
Supporting Evidence
- No primary mutations for integrase inhibitor resistance were found in the HIV-2 sequences.
- Most patients were receiving NRTI+PI-based regimens at the time of the study.
- Median HIV-2 plasma viral load was 2.76 log10 copies/ml.
- 37 out of 39 patients were infected with group A HIV-2.
Takeaway
This study looked at HIV-2 in Senegal and found that it is mostly treatable with new drugs, as it doesn't have the usual resistance mutations.
Methodology
PCR amplification and analysis of HIV-2 integrase sequences from 39 INI-naive adults.
Limitations
The study is limited to a specific geographic region and may not represent all HIV-2 populations.
Participant Demographics
{"females_percentage":72,"age_median":48,"age_range":"22-61"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website